for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adverum Biotechnologies Inc

ADVM.OQ

Latest Trade

6.09USD

Change

0.80(+15.12%)

Volume

896,090

Today's Range

5.50

 - 

6.34

52 Week Range

2.62

 - 

16.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.29
Open
5.54
Volume
896,090
3M AVG Volume
41.99
Today's High
6.34
Today's Low
5.50
52 Week High
16.38
52 Week Low
2.62
Shares Out (MIL)
64.46
Market Cap (MIL)
340.99
Forward P/E
-5.14
Dividend (Yield %)
--

Next Event

Q3 2019 Adverum Biotechnologies Inc Earnings Release

Latest Developments

More

Adverum Biotechnologies Q2 Loss Per Share $0.23

Adverum Biotechnologies Provides Update On Optic Phase 1 Trial For Advm-022 In Wet AMD

Adverum Biotechnologies Reports Q1 Loss Per Share $0.23

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.

Industry

Biotechnology & Drugs

Contact Info

1035 Obrien Dr

+1.650.6569323

https://adverum.com/

Executive Leadership

Patrick Machado

Independent Chairman of the Board

Leone D. Patterson

Chief Executive Officer, Director

Thomas Leung

Chief Financial Officer

Aaron Osborne

Chief Medical Officer

Mehdi Gasmi

Director

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.140

2017

-1.290

2018

-1.180

2019(E)

-1.028
Price To Earnings (TTM)
--
Price To Sales (TTM)
377.62
Price To Book (MRQ)
1.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-30.38
Return on Equity (TTM)
-28.94

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up